MGI Tech 将来の成長

Future 基準チェック /06

MGI Tech利益と収益がそれぞれ年間95.6%と11.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-0.9% 95.2%なると予測されています。

主要情報

95.6%

収益成長率

95.2%

EPS成長率

Life Sciences 収益成長	31.9%
収益成長率	11.4%
将来の株主資本利益率	-0.9%
アナリストカバレッジ	Good
最終更新日	08 Nov 2024

今後の成長に関する最新情報

Recent updates

MGI Tech Co., Ltd.'s (SHSE:688114) Shares Climb 35% But Its Business Is Yet to Catch Up

Oct 02

Things Look Grim For MGI Tech Co., Ltd. (SHSE:688114) After Today's Downgrade

Aug 30

Is MGI Tech Co., Ltd. (SHSE:688114) Trading At A 26% Discount?

Jun 03

Newsflash: MGI Tech Co., Ltd. (SHSE:688114) Analysts Have Been Trimming Their Revenue Forecasts

Apr 29

Is MGI Tech (SHSE:688114) Using Debt In A Risky Way?

Mar 28

Investor Optimism Abounds MGI Tech Co., Ltd. (SHSE:688114) But Growth Is Lacking

Feb 29

業績と収益の成長予測

SHSE:688114 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,818	-35	-59	521	6
12/31/2025	3,445	-148	-238	365	7
12/31/2024	2,776	-425	-80	322	6
9/30/2024	2,576	-873	-1,373	-829	N/A
6/30/2024	2,677	-808	-1,551	-741	N/A
3/31/2024	2,823	-659	-1,504	-637	N/A
12/31/2023	2,911	-607	-1,628	-870	N/A
9/30/2023	3,145	-193	-2,723	-1,543	N/A
6/30/2023	3,313	1,585	-456	602	N/A
3/31/2023	3,630	1,534	-110	855	N/A
12/31/2022	4,231	2,026	483	1,421	N/A
9/30/2022	4,372	2,046	2,213	2,554	N/A
6/30/2022	4,331	402	490	660	N/A
3/31/2022	4,169	613	692	925	N/A
12/31/2021	3,929	484	756	1,073	N/A
9/30/2021	3,887	555	150	548	N/A
12/31/2020	2,780	261	-493	5	N/A
12/31/2019	1,091	-244	-406	-195	N/A
12/31/2018	1,097	125	605	997	N/A
12/31/2017	802	-42	N/A	92	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 688114今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 688114今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 688114今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 688114の収益 ( 11.4% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 688114の収益 ( 11.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 688114 3 年以内に赤字になると予測されています。

MGI Tech 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 18%

Price target decreased by 22% to CN¥60.48

Price target decreased by 13% to CN¥87.32

Consensus EPS estimates have been downgraded.

Consensus revenue estimates fall by 13%

Recent updates

Consensus revenue estimates fall by 18%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

MGI Tech Co., Ltd.'s (SHSE:688114) Shares Climb 35% But Its Business Is Yet to Catch Up

MGI Tech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Things Look Grim For MGI Tech Co., Ltd. (SHSE:688114) After Today's Downgrade

Price target decreased by 22% to CN¥60.48

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MGI Tech Co., Ltd. Launches DNBSEQ-G400RS FluoXpert in the APAC Region at Medlab Asia & Asia Health 2024

MGI Tech Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

MGI Tech Co., Ltd. Launches Whole Workflow Solution for Agricultural Large-Scale Low-Pass Whole Genome Sequencing At PAG Asia 2024

MGI Tech Co., Ltd. Shares New Data on Core DENBSEQ Technology and Showcases Latest Sequencing Innovations At ESHG 2024

Is MGI Tech Co., Ltd. (SHSE:688114) Trading At A 26% Discount?

Now 21% undervalued after recent price drop

MGI Tech Showcases Life Science Excellence At ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer

Newsflash: MGI Tech Co., Ltd. (SHSE:688114) Analysts Have Been Trimming Their Revenue Forecasts

Price target decreased by 13% to CN¥87.32

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

MGI Tech Presents Latest Storage Product Series at ISBER 2024

Now 22% undervalued after recent price drop

MGI Tech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Is MGI Tech (SHSE:688114) Using Debt In A Risky Way?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor Optimism Abounds MGI Tech Co., Ltd. (SHSE:688114) But Growth Is Lacking

Now 20% overvalued

MGI Tech Co., Ltd. Unveils Comprehensive Expansion of Automation Product Lines for Life Science and Healthcare Research

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates have been downgraded.

MGI Tech Co., Ltd. (SHSE:688114) announces an Equity Buyback for CNY 500 million worth of its shares.

MGI Tech Co., Ltd. (SHSE:688114) announces an Equity Buyback for CNY 500 million worth of its shares.

Mgi Unveils Latest Mgisp-Nex and Mgiflp-L50 Automation Systems At Medlab Asia & Asia Health 2023

Consensus revenue estimates fall by 13%

Now 21% undervalued

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.004 in 2Q 2022)

MGI Tech Co., Ltd. to Report First Half, 2023 Results on Aug 11, 2023

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Full year 2022 earnings released: EPS: CN¥5.22 (vs CN¥1.30 in FY 2021)

MGI Tech Co., Ltd. Introduces its Ultra-High Throughput Sequencer DNBSEQ-T20×2 at MEDLAB Middle East

MGI Tech Co., Ltd. Announces That It Will Introduce Many of Its Latest Gene Sequencing Platforms and Sample Preparation System At MEDLAB Middle East 2023

MGI Announces European Launch of New MGISP-Smart 8 Automated Sample Preparation System and Empowerment Program At MEDICA to Further Access to Genomics

MGI Tech Co., Ltd. Launches Ultra High Speed DNBSEQ-G99 Gene Sequencer with Mid to Low Range Throughput

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘